Vicia Faba Supplement for Muscle Recovery
Recruiting in Palo Alto (17 mi)
Overseen byKris Osterberg, PhD, RD
Age: 18 - 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: PepsiCo Global R&D
Must not be taking: Testosterone, Estrogen, Creatine, NSAIDS
Disqualifiers: G6PD deficiency, Alcohol abuse, Pregnancy, Unstable conditions, Neurological disorders, others
Trial Summary
What is the purpose of this trial?To investigate the effect of Vicia faba protein concentrate, a protein derived from Fava bean extract, on delayed onset muscle soreness (DOMS). Participants receive either 2.4g/day of PeptiStrong® supplement capsules or placebo capsules for 14 days until a strenuous exercise session. For the last 3 days, 2/3 of them stay on the same treatment and 1/3 of them switch from placebo to PeptiStrong®.
Do I need to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but you must avoid additional supplements, especially protein-based ones, during the study.
What data supports the effectiveness of the treatment Vicia Faba Hydrolysate for muscle recovery?
Research suggests that a hydrolysate derived from Vicia faba, known as NPN_1, can help reduce muscle loss and promote muscle health in a mouse model of muscle atrophy. This treatment increased protein synthesis and improved muscle fiber composition, indicating potential benefits for muscle recovery.
12345Is Vicia Faba Supplement safe for human use?
Research on Vicia Faba (faba bean) shows that it contains anti-nutritional substances like vicine and convicine, which can affect growth and protein synthesis in animals. However, studies on chickens fed with faba beans showed no adverse effects on health or growth, suggesting it might be safe, but more human-specific research is needed.
13467How does Vicia Faba Supplement for Muscle Recovery differ from other treatments?
Vicia Faba Supplement is unique because it uses fava bean protein, which has been studied for its potential to influence muscle protein synthesis and reduce muscle atrophy. Unlike other treatments, it may offer a nutritional approach to muscle recovery by potentially enhancing protein synthesis and reducing inflammation, although its effectiveness in humans is still under investigation.
12345Eligibility Criteria
This trial is for men and women aged 18-45 who are moderately active, have a BMI of 18.5-29.9, don't smoke, and can fast overnight before tests. They must not drink alcohol before test days or take other supplements during the study, especially protein-based ones. Participants should maintain their normal diet and light exercise routine throughout the study.Inclusion Criteria
I am between 18 and 45 years old.
Moderately active (exercise 3-5 days per week)
Fluent in reading, writing, and speaking English
+9 more
Exclusion Criteria
I am taking testosterone or estrogen supplements, not for birth control.
I have not been in any clinical trials in the last 30 days or PepsiCo trials in the last 6 months.
I have health issues that could stop me from exercising.
+15 more
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Treatment
Participants receive either 2.4g/day of PeptiStrong® supplement capsules or placebo capsules for 14 days until a strenuous exercise session. For the last 3 days, 2/3 of them stay on the same treatment and 1/3 of them switch from placebo to PeptiStrong®.
17 days
Exercise and Recovery
Participants undergo a strenuous exercise session followed by monitoring of muscle strength recovery and soreness.
3 days
Daily assessments
Follow-up
Participants are monitored for safety and effectiveness after treatment
4 weeks
Participant Groups
The trial examines if PeptiStrong®, a Fava bean-derived protein supplement (2.4g/day), helps with muscle soreness after strenuous exercise compared to placebo capsules over 14 days. Some participants will switch from placebo to PeptiStrong® for the last three days.
3Treatment groups
Experimental Treatment
Placebo Group
Group I: PeptiStrong® 3 daysExperimental Treatment1 Intervention
14 days of Placebo followed by 3 days of PeptiStrong®
Group II: PeptiStrong® 17 daysExperimental Treatment1 Intervention
PeptiStrong® capsules 2.4 grams/day for 17 days
Group III: PlaceboPlacebo Group1 Intervention
PeptiStrong® capsules 2.4 grams per day for 17 days
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Gatorade Sports Science Institute at IMG AcademyBradenton, FL
Loading ...
Who Is Running the Clinical Trial?
PepsiCo Global R&DLead Sponsor
References
Developmental changes on protein turnover in growing rats fed on diets containing field beans (Vicia faba L.) as source of protein. [2018]The effects of nutrition with Vicia Faba L. administered at two different levels (12 and 18% protein) on the developmental changes of protein turnover were investigated in the rat. The myofibrillar gain and synthesis values were lower in the animals fed on legume protein as compared with casein-fed controls, while no differences were found in myofibrillar degradation during the three periods of time evaluated (0-14, 14-28 and 28-45 days). The fractional myofibrillar gain, breakdown and synthesis calculated as the sum of both, decreased with age in all the dietary groups. The antinutritional effects of the inclusion of Vicia faba L. in diets were more evident in the first 28 days, and attributed to a decreased muscle protein synthesis.
The Effect of Fava Bean (Vicia faba L.) Protein Ingestion on Myofibrillar Protein Synthesis at Rest and after Resistance Exercise in Healthy, Young Men and Women: A Randomised Control Trial. [2023]The aim of the present study was to evaluate the effect of feeding fava bean (Vicia faba L.) protein (FBP) on resting and post-exercise myofibrillar fractional synthetic rate (myoFSR). In a parallel, double-blind, randomised control trial, sixteen young, healthy recreationally active adults (age = 25 (5) years, body mass = 70 (15) kg, stature = 1.72 (0.11) m, mean (SD)) ingested 0.33 g·kg-1 FBP (n = 8) or a negative control (CON, i.e., EAA-free mixture) (n = 8), immediately after a bout of unilateral knee-extensor resistance exercise. Plasma, saliva, and m. vastus lateralis muscle samples were obtained pre-ingestion and 3 h post-ingestion. MyoFSR was calculated via deuterium labelling of myofibrillar-bound alanine, measured by gas chromatography-pyrolysis-isotope ratio mass spectrometry (GC-Pyr-IRMS). Resistance exercise increased myoFSR (p = 0.012). However, ingestion of FBP did not evoke an increase in resting (FBP 29 [-5, 63] vs. CON 12 [-25, 49]%, p = 0.409, mean % change [95% CI]) or post-exercise (FBP 78 [33, 123]% vs. CON 58 [9, 107]%, p = 0.732) myoFSR. Ingestion of 0.33 g·kg-1 of FBP does not appear to enhance resting or post-exercise myoFSR in young, healthy, recreationally active adults.
Correlation among growth rate and organ weights of rats fed on diets containing Vicia faba L. or casein as sources of protein at different levels. [2018]A significant impairment in the rate of growth, food efficiency and daily gain along with a decrease in the weight of skeletal muscle, carcass, viscera and liver was found in rats fed for a period of seven weeks on raw legume Vicia faba L. at different levels with respect to the controls on casein. Correlations between body weight and the weights of the structures were studied.
Preclinical Evaluation of a Food-Derived Functional Ingredient to Address Skeletal Muscle Atrophy. [2021]Skeletal muscle is the metabolic powerhouse of the body, however, dysregulation of the mechanisms involved in skeletal muscle mass maintenance can have devastating effects leading to many metabolic and physiological diseases. The lack of effective solutions makes finding a validated nutritional intervention an urgent unmet medical need. In vitro testing in murine skeletal muscle cells and human macrophages was carried out to determine the effect of a hydrolysate derived from vicia faba (PeptiStrong: NPN_1) against phosphorylated S6, atrophy gene expression, and tumour necrosis factor alpha (TNF-α) secretion, respectively. Finally, the efficacy of NPN_1 on attenuating muscle waste in vivo was assessed in an atrophy murine model. Treatment of NPN_1 significantly increased the phosphorylation of S6, downregulated muscle atrophy related genes, and reduced lipopolysaccharide-induced TNF-α release in vitro. In a disuse atrophy murine model, following 18 days of NPN_1 treatment, mice exhibited a significant attenuation of muscle loss in the soleus muscle and increased the integrated expression of Type I and Type IIa fibres. At the RNA level, a significant upregulation of protein synthesis-related genes was observed in the soleus muscle following NPN_1 treatment. In vitro and preclinical results suggest that NPN_1 is an effective bioactive ingredient with great potential to prolong muscle health.
Hormone-related, muscle-specific changes in protein metabolism and fiber type profile after faba bean intake. [2017]Male growing Wistar rats were fed, over 15 days, isoenergetic (16.72 +/- 0.49 MJ) and isoproteic (11%) diets containing either lactalbumin or raw Vicia faba L. (Vf) as the sole source of protein. Compared with pair-fed controls (PF), soleus muscles of Vf-fed rats showed increased (P
Toward a high-throughput method for determining vicine and convicine levels in faba bean seeds using flow injection analysis combined with tandem mass spectrometry. [2018]Although faba bean provides environmental and health benefits, vicine and convicine (v-c) limit its use as a source of vegetable protein. Crop improvement efforts to minimize v-c concentration require low-cost, rapid screening methods to distinguish between high and low v-c genotypes to accelerate development of new cultivars and to detect out-crossing events. To assist crop breeders, we developed a unique and rapid screening method that uses a 60 s instrumental analysis step to accurately distinguish between high and low v-c genotypes. The method involves flow injection analysis (FIA) coupled with tandem mass spectrometry (i.e., selective reaction monitoring, SRM). Using seeds with known v-c levels as calibrants, measured v-c levels were comparable with liquid chromatography (LC)-SRM results and the method was used to screen 370 faba bean genotypes. Widespread use of FIA-SRM will accelerate breeding of low v-c faba bean, thereby alleviating concerns about anti-nutritional effects of v-c in this crop.
Growth Performance of Local Chicken Breeds, a High-Performance Genotype and Their Crosses Fed with Regional Faba Beans to Replace Soy. [2020]The faba bean (Vicia faba L.) is a native protein crop and considered a promising alternative to soybeans. Due to its anti-nutritive substances such as vicin and convicin (VC) its use in animal nutrition has been restricted. In the present study, two consecutive experiments were conducted to analyse the effects of feeding 20% faba beans, which differ in their VC content on fattening performance and slaughter traits of different chicken genotypes. In a first trial, purebred male chickens of the local breeds Bresse Gauloise and Vorwerkhuhn as well as of a high-performance White Rock line were tested. In a second trial, crossbreds of them were evaluated: Vorwerkhuhn x Bresse Gauloise, Vorwerkhuhn x White Rock, Bresse Gauloise x White Rock. Daily weight gain and feed intake were recorded until slaughter at approximately 2100 g. At slaughter the final live weight, carcass yield and the weights of the valuable parts (breasts and legs) were measured. For the genotypes studied, no adverse or undesirable effects of both VC-rich and VC-poor faba beans in the feedstuff were detected regarding body weight development, carcass quality, and fattening parameters. Furthermore, there was no indication that the birds' health was impaired.